Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accumulated Expenses: 2017-2023

Historic Accumulated Expenses for Arcus Biosciences (RCUS) over the last 5 years, with Jun 2023 value amounting to $15.0 million.

  • Arcus Biosciences' Accumulated Expenses rose 3.89% to $15.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $15.0 million, marking a year-over-year increase of 3.89%. This contributed to the annual value of $25.0 million for FY2022, which is 47.06% up from last year.
  • Per Arcus Biosciences' latest filing, its Accumulated Expenses stood at $15.0 million for Q2 2023, which was up 25.00% from $12.0 million recorded in Q1 2023.
  • In the past 5 years, Arcus Biosciences' Accumulated Expenses registered a high of $25.0 million during Q4 2022, and its lowest value of $5.0 million during Q4 2019.
  • For the 3-year period, Arcus Biosciences' Accumulated Expenses averaged around $15.2 million, with its median value being $14.8 million (2021).
  • In the last 5 years, Arcus Biosciences' Accumulated Expenses spiked by 258.18% in 2019 and then slumped by 63.92% in 2020.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Accumulated Expenses stood at $5.0 million in 2019, then spiked by 92.79% to $9.5 million in 2020, then surged by 78.14% to $17.0 million in 2021, then skyrocketed by 47.06% to $25.0 million in 2022, then rose by 3.89% to $15.0 million in 2023.
  • Its Accumulated Expenses was $15.0 million in Q2 2023, compared to $12.0 million in Q1 2023 and $25.0 million in Q4 2022.